NCT01523392已完成4 期
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Inhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose
研究概览
简要总结
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.
详细描述
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in African American Patients with Stable Coronary Artery Disease
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of signed and dated informed consent before initiation of any study-related procedures
- •Male or female patients aged 18 years or older
- •Documented stable CAD fulfilling and taking 75-100mg ASA daily treatment
- •Females must be post menopausal or surgically sterile Self-identified as African American
排除标准
- •Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, ASA dose other than 75 to 100 mg daily) during study period
- •Patients who had ACS or stent placed within 12 months of screening Patients with a history of moderate or severe hepatic impairment
- •Current smokers, including the use of tobacco containing products in the past 1 month of randomization Patients required dialysis
研究组 & 干预措施
Ticagrelor
Experimental
干预措施: Ticagrelor (Drug)
Clopidogrel
Active Comparator
干预措施: Clopidogrel (Drug)
结局指标
主要结局
Inhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose
时间窗: At 2 hours after the loading dose
次要结局
- Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 Hour and 8 Hours After Loading Dose(At 0.5 hour and 8 hours after the loading dose)
- Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 Hours and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8(At 2 hours and 8 hours on Day 7 after multiple doses and at end of dosing interval on Day 8)
- Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses(Predose, 0.5 hour, 2 hours, 8 hours from loading dose; 0, 2 hours, 8 hours and 12 hours from last dose)
- AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses(Predose, 0.5 hour, 2 hours, 8 hours from loading dose and 0, 2 hours, 8 hours and 12 hours from last dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
A Pharmacodynamic Study With Ticagrelor in Hispanic PatientsStable Coronary Artery DiseaseNCT01523366AstraZeneca53
已完成
2 期
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-respondersStable Coronary Artery DiseaseNCT00642811AstraZeneca98
已完成
4 期
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome PatientsAcute Coronary SyndromeNCT01603082AstraZeneca343
已完成
1 期
PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)Sickle Cell DiseaseNCT03492931AstraZeneca21
已完成
2 期
A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With AspirinCoronary Artery DiseaseNCT00528411AstraZeneca123